N-甲基-N-(2-甲基苯基)-3-硝基-4-(2-噻唑磺酰基)-苯胺 | 217438-17-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-甲基-N-(2-甲基苯基)-3-硝基-4-(2-噻唑磺酰基)-苯胺
• 中文别名: N-甲基-N-(2-甲基苯基)-3-硝基-4-(2-噻唑基亚磺酰基)-苯甲酰胺
• 英文名称: N-methyl-N-(2-methylphenyl)-3-nitro-4-(1,3-thiazol-2-ylsulfinyl)benzamide
• CAS: 217438-17-0
• 化学式: C18H15N3O4S2
• 分子量: 401.5
• InChiKey: YXHLPJQQPOMPGE-UHFFFAOYSA-N

物化性质

• 溶解度：
  二甲基亚砜：>5mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  144
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• Use of CGRP antagonist compounds for treatment of psoriasis
  申请人：NEPSONE EHF

  公开号：US10668132B2

  公开（公告）日：2020-06-02

  A method for treating, remedying, or preventing psoriasis by administering a therapeutically effective dose of at least one CGRP antagonist compound in a pharmaceutically acceptable formulation. The method for treating, remedying, or preventing psoriasis by administering topically and to the pre-psoriatic rim a therapeutically effective dose of at least one CGRP antagonist compound in a pharmaceutically acceptable formulation.

  一种治疗、补救或预防银屑病的方法，通过给药治疗有效剂量的至少一种CGRP拮抗剂化合物的药学上可接受的制剂。一种治疗、补救或预防银屑病的方法，通过对银屑病前缘局部施用药学上可接受的制剂中至少一种CGRP拮抗剂化合物的治疗有效剂量。
• Methods of treating inflammatory skin disorders
  申请人：NEPSONE EHF

  公开号：US11266718B2

  公开（公告）日：2022-03-08

  A method for treating, remedying, or preventing inflammatory skin disorders by administering a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation. The method for treating, remedying, or preventing an inflammatory skin disorder by administering topically and to the pre-psoriatic rim a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation.

  一种治疗、补救或预防炎症性皮肤病的方法，通过在药学上可接受的制剂中给药治疗有效剂量的至少一种降钙素基因相关肽受体的拮抗剂。治疗、补救或预防炎症性皮肤病的方法，通过局部给药和给银屑病前边缘注射治疗有效剂量的至少一种降钙素基因相关肽受体拮抗剂，该拮抗剂为药学上可接受的制剂。
• Targeting cell tropism receptors to inhibit cytomegalovirus infection
  申请人：UNIVERSITY OF MASSACHUSETTS

  公开号：US11484570B2

  公开（公告）日：2022-11-01

  Methods for treating or reducing the risk of a cytomegalovirus infection in a subject that include administering one or more of an inhibitor of Deleted in Malignant Brain Tumors 1 (DMBT1), an inhibitor of OR14I1, or an inhibitor of adenylyl cyclases.

  治疗或降低受试者巨细胞病毒感染风险的方法，包括施用恶性脑肿瘤删减1（DMBT1）抑制剂、OR14I1抑制剂或腺苷酸环化酶抑制剂中的一种或多种。
• USE OF CGRP ANTAGONIST COMPOUNDS FOR TREATMENT OF PSORIASIS
  申请人：Actavis Group hf.

  公开号：EP1556020B1

  公开（公告）日：2009-02-25
• METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS
  申请人：DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH

  公开号：US20190070178A1

  公开（公告）日：2019-03-07

  The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.